[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Priothera SAS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":41},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100472265",false,"NCT05429632","Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT","Randomized, Double-blind, Placebo-controlled, Multi-center Phase III Study to Evaluate the Efficacy and Safety of Mocravimod as Adjunctive and Maintenance Treatment in Adult AML Patients Undergoing Allogeneic HCT","MO-TRANS","Inclusion Criteria:\n\n* Diagnosis of AML (excluding acute promyelocytic leukemia) according to the WHO 2022 classification of AML and related precursor neoplasm, including AML with myelodysplasia-related gene mutations\n* European Leukemia Net (ELN) high-risk or intermediate-risk AML in CR1, or AML of any risk in CR2, \\[CRi\\] is also allowable\n* Planned allogeneic HCT from fully matched related or unrelated donor with no more than 1 antigen mismatch or planned use of haploidentical donor using PBSC graft\n* Any conditioning regimen with a Transplant Conditioning Score (TCI) ≥ 1.5\n* Planned use of TAC-based GvHD prophylaxis\n* age ≥ 18 years and ≤ 75 years\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\nExclusion Criteria:\n\n* Use of CsA, anti-thymocyte globulin (ATG), alemtuzumab, abatacept for GvHD prophylaxis\n* Diagnosis of macular edema during screening\n* Cardiac\u002Fpulmonary\u002Fhepatic\u002Frenal dysfunction\n* Hepatic dysfunction as defined by aspartate aminotransferase (AST) and\u002For alanine aminotransferase (ALT) \\> 2.5 x upper limit of normal (ULN); or total bilirubin \\> 1.5 mg\u002FdL\n* Renal dysfunction with estimated creatinine clearance \\\u003C 45 mL\u002Fmin by the Cockcroft-Gault formula\n\n  * Diabetes mellitus\n  * History or presence of uveitis at screening\n  * History or diagnosis of macular edema","ALL","18 Years","75 Years",{"count":20,"type":21},366,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multi-center, randomized, double-blinded, placebo controlled trial.",[27],"Adult Acute Myeloid Leukemia","RECRUITING","2026-06-18",{"date":31,"type":32},"2026-06-22","ACTUAL",{"date":34,"type":32},"2022-06-16",{"date":36,"type":21},"2029-11",{"name":38,"class":39},"Priothera SAS","INDUSTRY",110,""]